Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax

  • STATUS
    Recruiting
  • participants needed
    80
  • sponsor
    Memorial Sloan Kettering Cancer Center
Send
Updated on 16 February 2024
See if I qualify
remission
monoclonal antibodies
formalin-fixed paraffin-embedded
chronic lymphocytic leukemia
lymphoid leukemia
lymphoma
leukemia
monoclonal protein
residual tumor
bone marrow biopsy
venetoclax
lymphocytic leukemia
minimal residual disease
antibody therapy

Summary

This study will find out whether people with CLL or SLL who have received treatment with venetoclax, either alone or in combination with another drug, and who are found to be MRD-negative, can stop treatment with venetoclax and remain off-treatment for 12 months or more. The researchers will also see whether study participants remain MRD-negative after they stop treatment with venetoclax.

Description

Screening Phase:

Patients will be identified by clinical investigators at participating centers. Patients who sign the screening consent patients will undergo an MRD assessment with the clonoSEQ assay. If the assessment identifies the patient to be MRD negative, the patient will undergo a repeat MRD assessment no less than 28 days later. If two consecutive MRD assessments indicate MRD-negativity, the patient will then be directed to sign the study intervention phase informed consent form and will undergo the rest of the screening process.

Enrollment

Once the patient fulfills all eligibility criteria, the patient will be enrolled into one of two cohorts based on the type of therapy they are receiving at the time of enrolled:

Cohort A: Venetoclax monotherapy at time of enrollment.

Cohort B: Venetoclax with anti CD20 monoclonal antibody at time of enrollment (The latter includes patients who initiated anti CD20 monoclonal antibody with venetoclax and have since completed the anti CD20 monoclonal antibody portion of the regimen.)

Details
Condition Chronic Lymphocytic Leukemia, lymphocytic leukemia, chronic, Chronic Lymphocytic Leukemia, lymphocytic leukemia, chronic
Age 18years - 100years
Treatment Venetoclax monotherapy, Venetoclax with anti CD20 monoclonal antibody
Clinical Study IdentifierNCT04419519
SponsorMemorial Sloan Kettering Cancer Center
Last Modified on16 February 2024

Eligibility

 Yes No Not Sure

Inclusion Criteria

-years-old
Diagnosis of Chronic lymphocytic leukemia or Small lymphocytic lymphoma confirmed by the enrolling institution
Receiving treatment with a venetoclax-based regimen as defined below
Venetoclax monotherapy
Venetoclax in combination with anti CD20 monoclonal antibody (Patients must have completed the anti CD20 monoclonal antibody portion of the regimen prior to discontinuing therapy)
Patients must be receiving commercially supplied venetoclax (and anti CD20 monoclonal antibody)Have 3-5 bone marrow aspirate slides (fresh or banked), 3-5 FFPE slides (fresh or banked), available banked tumor cells or DNA, or fresh blood sample collected from the patient at any time from original diagnosis of CLL to present to identify the CLL clone(s) for future MRD assessments by clonoSEQ
The screening ID sample (high disease burden sample) can be sent prior to start of venetoclax-based therapy to identify the clone for tracking
Study Intervention Phase Inclusion Criteria
Patients must have received venetoclax-based therapy for at least 6 months (including dose interruptions)
Patients must have two MRD-negative assessments (defined by 10^-5 sensitivity) on the peripheral blood by the clonoSEQ assay at least 28 days apart. Given that MRD status is a dynamic endpoint which may improve with time, if a patient is screen failure based on MRD status (i.e. MRD positive at the 10-5 sensitivity), they may be rescreened for MRD status every three months to assess for study eligibility. Patients must have achieved a complete or partial remission with the venetoclax-based regimen. Criteria for remission are per iwCLL 2018 guidelines. For this protocol, bone marrow biopsy/aspirate evaluation is not necessary to determine remission status

Exclusion Criteria

Participation in a clinical trial that supplies venetoclax and/or anti CD20 monoclonal antibody
Unwilling or unable to participate in all required study evaluations and procedures
Unable to understand the purpose and risks of the study and to provide a signed and dated informed consent form (ICF) and authorization to use protected health information (in accordance with national and local patient privacy regulations)
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

remission
monoclonal antibodies
formalin-fixed paraffin-embedded
chronic lymphocytic leukemia
lymphoid leukemia
lymphoma
leukemia
monoclonal protein
residual tumor
bone marrow biopsy
venetoclax
lymphocytic leukemia
minimal residual disease
antibody therapy

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.